Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Melanoma/Skin Cancer
•
Medical Oncology
•
General Internal Medicine
How do you manage dabrafenib fever?
Decrease the dose? Treatment break? Steroids?
Medical Oncologist
Tough problem to manage. I've tried numerous strategies with unpredictable success. Prednisone 5mg BID usually works if you want to keep full dose. Otherwise, a dose delay and likely reduction of dab will be necessary.
Sign in or Register to read more
1071
Related Questions
Should GLP-1 agonists be held during chemotherapy?
How would you sequence lifileucel (TIL therapy) in a patient with metastatic melanoma who is BRAF wild-type (BRAF WT) and progressed on adjuvant Nivolumab?
Do you use direct oral anticoagulants to treat port-a-cath related VTE in patients with an active malignancy?
How would you treat a patient with selective IgM deficiency on IVIG infusions with a new diagnosis of CLL?
How would you treat locally advanced melanoma of the scalp with several in transit lesions and a metastatic lesion to the parotid if the patient is progressing on immunotherapy such as pembrolizumab?
When would you offer neoadjuvant immunotherapy prior to Mohs surgery in a locally advanced squamous cell carcinoma for which clearance may require enucleation?
Is there any definitive contraindication to use tamoxifen in patients with a brain aneurysm that is being monitored?
In what situations would you recommend adjuvant radiation therapy for patients with locally advanced and/or recurrent basal cell carcinoma that receive vismodegib followed by surgery?
What is the optimal management of pain and loss of function due to pathologic compression fractures?
Do patients with central adrenal insufficiency on maintenance hydrocortisone therapy require doubling of their corticosteroid during chemotherapy cycles?